A review of a multifactorial probability-based model for classification of BRCA1 and BRCA2 variants of uncertain significance (VUS)

Noralane Morey Lindor, Lucia Guidugli, Xianshu Wang, Maxime P. Vallée, Alvaro N A Monteiro, Sean Tavtigian, David E. Goldgar, Fergus J Couch

Research output: Contribution to journalArticle

87 Citations (Scopus)

Abstract

Clinical mutation screening of the BRCA1 and BRCA2 genes for the presence of germline inactivating mutations is used to identify individuals at elevated risk of breast and ovarian cancer. Variants identified during screening are usually classified as pathogenic (increased risk of cancer) or not pathogenic (no increased risk of cancer). However, a significant proportion of genetic tests yields variants of uncertain significance (VUS) that have undefined risk of cancer. Individuals carrying these VUS cannot benefit from individualized cancer risk assessment. Recently, a quantitative "posterior probability model" for assessing the clinical relevance of VUS in BRCA1 or BRCA2, which integrates multiple forms of genetic evidence has been developed. Here, we provide a detailed review of this model. We describe the components of the model and explain how these can be combined to calculate a posterior probability of pathogenicity for each VUS. We explain how the model can be applied to public data and provide tables that list the VUS that have been classified as not pathogenic or pathogenic using this method. While we use BRCA1 and BRCA2 VUS as examples, the method can be used as a framework for classification of the pathogenicity of VUS in other cancer genes.

Original languageEnglish (US)
Pages (from-to)8-21
Number of pages14
JournalHuman Mutation
Volume33
Issue number1
DOIs
StatePublished - Jan 2012

Fingerprint

Virulence
Neoplasms
BRCA2 Gene
BRCA1 Gene
Germ-Line Mutation
Neoplasm Genes
Ovarian Neoplasms
Breast Neoplasms
Mutation

Keywords

  • BRCA1
  • BRCA2
  • Missense mutations
  • VUS classification

ASJC Scopus subject areas

  • Genetics
  • Genetics(clinical)

Cite this

A review of a multifactorial probability-based model for classification of BRCA1 and BRCA2 variants of uncertain significance (VUS). / Lindor, Noralane Morey; Guidugli, Lucia; Wang, Xianshu; Vallée, Maxime P.; Monteiro, Alvaro N A; Tavtigian, Sean; Goldgar, David E.; Couch, Fergus J.

In: Human Mutation, Vol. 33, No. 1, 01.2012, p. 8-21.

Research output: Contribution to journalArticle

Lindor, Noralane Morey ; Guidugli, Lucia ; Wang, Xianshu ; Vallée, Maxime P. ; Monteiro, Alvaro N A ; Tavtigian, Sean ; Goldgar, David E. ; Couch, Fergus J. / A review of a multifactorial probability-based model for classification of BRCA1 and BRCA2 variants of uncertain significance (VUS). In: Human Mutation. 2012 ; Vol. 33, No. 1. pp. 8-21.
@article{b0f91f7721784e4e9513ccd435caeb73,
title = "A review of a multifactorial probability-based model for classification of BRCA1 and BRCA2 variants of uncertain significance (VUS)",
abstract = "Clinical mutation screening of the BRCA1 and BRCA2 genes for the presence of germline inactivating mutations is used to identify individuals at elevated risk of breast and ovarian cancer. Variants identified during screening are usually classified as pathogenic (increased risk of cancer) or not pathogenic (no increased risk of cancer). However, a significant proportion of genetic tests yields variants of uncertain significance (VUS) that have undefined risk of cancer. Individuals carrying these VUS cannot benefit from individualized cancer risk assessment. Recently, a quantitative {"}posterior probability model{"} for assessing the clinical relevance of VUS in BRCA1 or BRCA2, which integrates multiple forms of genetic evidence has been developed. Here, we provide a detailed review of this model. We describe the components of the model and explain how these can be combined to calculate a posterior probability of pathogenicity for each VUS. We explain how the model can be applied to public data and provide tables that list the VUS that have been classified as not pathogenic or pathogenic using this method. While we use BRCA1 and BRCA2 VUS as examples, the method can be used as a framework for classification of the pathogenicity of VUS in other cancer genes.",
keywords = "BRCA1, BRCA2, Missense mutations, VUS classification",
author = "Lindor, {Noralane Morey} and Lucia Guidugli and Xianshu Wang and Vall{\'e}e, {Maxime P.} and Monteiro, {Alvaro N A} and Sean Tavtigian and Goldgar, {David E.} and Couch, {Fergus J}",
year = "2012",
month = "1",
doi = "10.1002/humu.21627",
language = "English (US)",
volume = "33",
pages = "8--21",
journal = "Human Mutation",
issn = "1059-7794",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - A review of a multifactorial probability-based model for classification of BRCA1 and BRCA2 variants of uncertain significance (VUS)

AU - Lindor, Noralane Morey

AU - Guidugli, Lucia

AU - Wang, Xianshu

AU - Vallée, Maxime P.

AU - Monteiro, Alvaro N A

AU - Tavtigian, Sean

AU - Goldgar, David E.

AU - Couch, Fergus J

PY - 2012/1

Y1 - 2012/1

N2 - Clinical mutation screening of the BRCA1 and BRCA2 genes for the presence of germline inactivating mutations is used to identify individuals at elevated risk of breast and ovarian cancer. Variants identified during screening are usually classified as pathogenic (increased risk of cancer) or not pathogenic (no increased risk of cancer). However, a significant proportion of genetic tests yields variants of uncertain significance (VUS) that have undefined risk of cancer. Individuals carrying these VUS cannot benefit from individualized cancer risk assessment. Recently, a quantitative "posterior probability model" for assessing the clinical relevance of VUS in BRCA1 or BRCA2, which integrates multiple forms of genetic evidence has been developed. Here, we provide a detailed review of this model. We describe the components of the model and explain how these can be combined to calculate a posterior probability of pathogenicity for each VUS. We explain how the model can be applied to public data and provide tables that list the VUS that have been classified as not pathogenic or pathogenic using this method. While we use BRCA1 and BRCA2 VUS as examples, the method can be used as a framework for classification of the pathogenicity of VUS in other cancer genes.

AB - Clinical mutation screening of the BRCA1 and BRCA2 genes for the presence of germline inactivating mutations is used to identify individuals at elevated risk of breast and ovarian cancer. Variants identified during screening are usually classified as pathogenic (increased risk of cancer) or not pathogenic (no increased risk of cancer). However, a significant proportion of genetic tests yields variants of uncertain significance (VUS) that have undefined risk of cancer. Individuals carrying these VUS cannot benefit from individualized cancer risk assessment. Recently, a quantitative "posterior probability model" for assessing the clinical relevance of VUS in BRCA1 or BRCA2, which integrates multiple forms of genetic evidence has been developed. Here, we provide a detailed review of this model. We describe the components of the model and explain how these can be combined to calculate a posterior probability of pathogenicity for each VUS. We explain how the model can be applied to public data and provide tables that list the VUS that have been classified as not pathogenic or pathogenic using this method. While we use BRCA1 and BRCA2 VUS as examples, the method can be used as a framework for classification of the pathogenicity of VUS in other cancer genes.

KW - BRCA1

KW - BRCA2

KW - Missense mutations

KW - VUS classification

UR - http://www.scopus.com/inward/record.url?scp=84857688644&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857688644&partnerID=8YFLogxK

U2 - 10.1002/humu.21627

DO - 10.1002/humu.21627

M3 - Article

C2 - 21990134

AN - SCOPUS:84857688644

VL - 33

SP - 8

EP - 21

JO - Human Mutation

JF - Human Mutation

SN - 1059-7794

IS - 1

ER -